RGCC tests
RGCC’s objective is to equip patients and clinicians with the most robust, reliable and accurate information about cancer so they can make informed decisions about healthcare choices. Our range of 11 tests is designed to discover, analyse and screen cancer cells at every step of the disease, and to provide vital information that can help clinicians to identify the best, and most effective, cancer treatments and therapies.
RGCC tests are only available to the RGCC Network of healthcare professionals. If you are a healthcare professional interested in learning more about the RGCC Network, please contact your local branch office. If you are a patient interested in ordering an RGCC test, you can request one through your personal healthcare provider, or contact one of our global network of healthcare providers. To find your nearest RGCC registered clinician, send us a message via our website.
Array comparative genomic hybridisation (aCGH) RGCC
Array comparative genomic hybridisation (aCGH) RGCC
The array comparative genomic hybridisation (aCGH) RGCC test is used to identify chromosomal abnormalities in a patient that could lead to cancer. RGCC scientists use a technique called array comparative genomic hybridisation (CGH) to spot abnormalities in a genome. This insight enables them to assess the likely risk of cancer developing and the potential location of a primary tumour. Array comparative genomic hybridisation (aCGH) RGCC is the most accurate test of its type available today and can help clinicians to understand more about a patient’s genes, giving them a powerful tool in the fight against cancer. RGCC tests are only available to the RGCC Network of healthcare professionals. See below for more details.
ChemoSNiP
ChemoSNiP
ChemoSNiP is an innovative test that uses an advanced scientific technique called pharmacogenomics to analyse how a patient’s body will respond to a specific drug. The ChemoSNiP test analyses a blood sample to identify for single nucleotide polymorphisms – variations in our DNA sequence that can affect if we develop cancer or if we respond to treatments with chemicals, drugs and other agents. ChemoSNiP provides clinicians with a powerful insight into which drugs are most effective at treating cancer. The results provide a personalised analysis that can be used to provide the most effective combination of drugs and treatments available. RGCC tests are only available to the RGCC Network of healthcare professionals. See below for more details.
Immune-Frame
Immune-Frame
The RGCC Immune-Frame test is used to assess the condition of a patient’s immune system. Scientists use the test to identify specific cellular markers that are responsible for switching a patient’s immune system on and off. The results of the RGCC Immune-Frame test can be used to analyse the status of a patient’s immune system, and to provide ongoing information about their health status. This information can be used by clinicians to advise on potential health risks a patient may face, and how these can be minimised.
Metastat RGCC
Metastat RGCC
Metastat RGCC is an advanced test to detect specific blood-borne markers that can accurately determine whether a secondary cancerous tumour is likely to develop and its potential location. During the test, we analyse a sample of a patient’s blood in our state-of-the-art laboratory to analyse, identify and measure circulating tumour cells (CTCs). Metastat RGCC is suitable for all patients who have received a confirmed cancer diagnosis. The test can accurately detect the development of secondary cancers or tumours and improve personalised cancer treatments.
Oncocount RGCC
Oncocount RGCC
Oncocount RGCC detects the presence of circulating tumour cells (CTCs) and their concentration in the blood. CTCs are a powerful biomarker, and their presence in the blood can act as an early warning sign that cancer is returning. The Oncocount RGCC test is designed as a follow-up test for patients who have cancer and are worried about the disease returning. Clinicians can use the Oncocount RGCC test to assess how effective cancer treatment is and the likelihood of cancer returning (relapse).
Onconomics Extracts
Onconomics Extracts
Onconomics Extracts is a unique and highly detailed test that provides information on how effective natural substances and plants extracts are at attacking circulating cancer cells (CTCs). The Onconomics Extracts test uses three unique and scientifically-proven methods to assess how effective natural treatments are at tackling cancer. The results provide a comprehensive and highly personalised analysis of the most effective natural treatments that patients can use to treat their cancer, alongside conventional therapies.
Onconomics RGCC
Onconomics RGCC
Onconomics RGCC provides highly detailed and accurate information about how effective specific anti-cancer drugs and targeted therapies are in treating cancer. The test combines a molecular and a cellular approach by incorporating two procedures: epigenetic analysis and viability assays. A sample of blood or tissue is analysed to test how effective specific therapies and treatments are at suppressing cancer. Together, the results of these two testing methods provide scientists and clinicians with a comprehensive breakdown of the most suitable and successful treatments for cancer.
Onconomics Plus RGCC
Onconomics Plus RGCC
Onconomics Plus RGCC test provides information about the effect of specific anti-cancer drugs, targeted therapies and natural treatments on the cancer cells in an individual patient. During the test, a sample of blood or tissue is analysed to test how effective specific therapies and treatments are at suppressing cancer. Together, the results of the extensive tests provide scientists and clinicians with a comprehensive breakdown of the most suitable and successful treatments for cancer. The results can be used by clinicians to design personalised and targeted cancer therapies with the highest chances of success.
Oncotrace RGCC
Oncotrace RGCC
Oncotrace RGCC is used to identify a primary tumour in a patient and to provide guidance about disease progression and future prognosis. During the test, a sample of blood is analysed to identify the presence and concentration of circulating tumour cells (CTCs) and their concentration. This test provides information about the presence of CTCs, their concentration and specific type (immunophenotype). The results of the test enable clinicians to identify the origin of a tumour where this is unknown and to provide information on the development of cancer and the prognosis.
Oncotrail RGCC
Oncotrail RGCC
Oncotrail RGCC provides crucial information on the presence of circulating tumour cells (CTCs) and their concentration in patients who have a confirmed diagnosis of specific forms of cancer, including breast, colon and prostate cancer. During the test, a sample of blood is analysed to identify the presence and concentration of CTC and their immunophenotype. The Oncotrail RGCC test isn’t used as a primary diagnostic test to confirm a cancer diagnosis, but provides essential information on the effectiveness of current cancer treatments. Follow-up tests can also be used to monitor a patient’s health and assess the risk of relapse.
RGCC CAMBISeq®
RGCC CAMBISeq®
RGCC CAMBISeq® is an innovative test that uses next-generation sequencing analysis on both DNA and RNA to provide clinicians with a crucial insight into cancer. The CAMBISeq – or cancer analysis, mutational burden and instability sequencing – test is used to identify variants in 500 genes that our scientists use as biomarkers to assess their sensitivity to immunotherapy. The results can predict how well a patient will respond to types of immunotherapy. RGCC CAMBISeq® is suitable for all patients who have a confirmed cancer diagnosis. The test can be used by clinicians to identify the best, and most effective, combinations of cancer treatments.